FGF-BP3 Activators
The FGF-BP3 Activators are a class of chemicals that can indirectly upregulate FGF-BP3 expression through various mechanisms. These chemicals target different components of signaling pathways that are known to negatively regulate FGF-BP3 expression, such as the MAPK, PI3K/Akt, and TGF-β signaling pathways. By inhibiting key signaling molecules in these pathways, these chemicals can indirectly increase FGF-BP3 expression.
For instance, p38 MAPK inhibitors like SB203580 and PD98059 can indirectly upregulate FGF-BP3 expression by suppressing the activation of p38 MAPK, a signaling protein that can negatively regulate FGF-BP3 expression. Similarly, PI3K inhibitors like LY294002 and wortmannin can indirectly increase FGF-BP3
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A small molecule inhibitor of p38 MAPK, a signaling protein that can negatively regulate FGF-BP3 expression. By inhibiting p38 MAPK, SB203580 can indirectly upregulate FGF-BP3 expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A specific inhibitor of the MAPK kinase MEK1, which is upstream of p38 MAPK in the MAPK signaling pathway. PD98059 can indirectly increase FGF-BP3 expression by blocking the activation of p38 MAPK. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A phosphatidylinositol 3-kinase (PI3K) inhibitor that can indirectly upregulate FGF-BP3 expression by interfering with the PI3K/Akt signaling pathway, which can negatively regulate FGF-BP3 expression. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor that can indirectly increase FGF-BP3 expression by blocking the PI3K/Akt signaling pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
A macrolide antibiotic that inhibits mTORC1, and can therefore indirectly increase FGF-BP3 expression by blocking the mTORC1 signaling pathway. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
A specific inhibitor of c-jun N-terminal kinases (JNKs), another member of the MAPK family that can negatively regulate FGF-BP3 expression. By inhibiting JNKs, DAPT can indirectly upregulate FGF-BP3 expression. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
A specific inhibitor of TGF-β receptor kinase 1 (TβR1), a key signaling component in the TGF-β signaling pathway. SB431542 can indirectly upregulate FGF-BP3 expression by blocking TGF-β signaling. | ||||||
SB-505124 | 694433-59-5 | sc-362794 sc-362794A | 10 mg 50 mg | $327.00 $1377.00 | 2 | |
An inhibitor of the SMAD family of transcription factors, which are downstream effectors of TGF-β signaling. SB505124 can indirectly upregulate FGF-BP3 expression by blocking SMAD-mediated transcriptional repression of FGF-BP3. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
An inhibitor of the SMAD4 transcription factor, which plays a critical role in TGF-β signaling. LDN-193189 can indirectly increase FGF-BP3 expression by blocking SMAD4-mediated transcriptional repression of FGF-BP3. | ||||||